Dogwood Therapeutics reported continued advancement of its Halneuron® program with positive interim Phase 2b data in chemotherapy-induced neuropathic pain and near completion of a synthetic formulation expected to enter Phase 3 development. The synthetic version aims to address manufacturing scalability and patent longevity. Concurrently, Dogwood is developing SP16 via a license agreement for neuropathy treatment. The company maintains sufficient liquidity but remains reliant on successful clinical outcomes and regulatory approval to transition from development-stage status.